Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Autologous Adipose Cells Therapy Clear all
Not listed Phase 1 Interventional

NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia

NCT05693558
View directory record Official record
Conditions
Congenital Pseudarthrosis of Tibia
Interventions
NVD-003, an autologous 3D scaffold free osteogenic graft
Biological
Lead sponsor
Novadip Biosciences
Industry
Eligibility
2 Years to 8 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 25, 2026, 4:57 PM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
HB-adMSCs, Placebo
Biological · Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 25, 2026, 4:57 PM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

NCT04029896
View directory record Official record
Conditions
Cerebral Palsy
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
3 Years and older · Male only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 25, 2026, 4:57 PM EDT
Terminated Not applicable Interventional

Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.

NCT01739504
View directory record Official record
Conditions
Osteoarthritis
Interventions
Liposuction with Local Anesthesia, Intra articular infusion of AD-SVF
Procedure · Biological
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 25, 2026, 4:57 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects

NCT05553132
View directory record Official record
Conditions
Cartilage Defect
Interventions
Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier
Combination Product
Lead sponsor
Daniel B. F. Saris
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Adipose Stem Cells for Traumatic Spinal Cord Injury

NCT03308565
View directory record Official record
Conditions
Spinal Cord Injuries, Paralysis
Interventions
Autologous, Adipose derived Mesenchymal Stem Cells
Biological
Lead sponsor
Mohamad Bydon
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

NCT02216630
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Adipose Derived Stem Cell (ADSC) Therapy
Drug
Lead sponsor
Kimera Society Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Davie, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 25, 2026, 4:57 PM EDT
Not listed Not applicable Interventional

Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction

NCT01601353
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tissue Genesis Cell Isolation System
Device
Lead sponsor
Tissue Genesis
Industry
Eligibility
40 Years to 70 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 25, 2026, 4:57 PM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI

NCT03925649
View directory record Official record
Conditions
Spinal Cord Injury at C5-C7 Level
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 25, 2026, 4:57 PM EDT
Withdrawn Phase 1 Interventional

Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia

NCT02099500
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Liposuction, Stem Cell Injection
Procedure · Other
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 25, 2026, 4:57 PM EDT
Active, not recruiting Phase 2 Interventional

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

NCT06800404
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Interventions
Autologous HB-adMSCs
Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 25, 2026, 4:57 PM EDT
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome

NCT03722303
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Fat Injection, Steroid Injection
Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 25, 2026, 4:57 PM EDT
Recruiting Not applicable Interventional

Autologous Fat Grafting for the Treatment of Chronic Tendinopathy

NCT07748793
View directory record Official record
Conditions
Chronic Tendinopathy
Interventions
Adipose Stem/Stromal Cells for Enthesis/Tendon Therapy (ASSET) Injection
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 4:57 PM EDT
Active, not recruiting Phase 2 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients

NCT04520373
View directory record Official record
Conditions
Spinal Cord Injuries, Paralysis
Interventions
Best Medical Management: Occupational and Physical Therapy, Autologous, Adipose Derived Mesenchymal Stem Cells
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 25, 2026, 4:57 PM EDT
Suspended Not applicable Interventional

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

NCT04064879
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
AD-SVF
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis

NCT02805855
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Autologous Adipose-Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Jacob L. Sellon, M.D.
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 25, 2026, 4:57 PM EDT
Not listed Not applicable Interventional

Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints

NCT03166410
View directory record Official record
Conditions
Osteoarthritis
Interventions
Cell injection
Procedure
Lead sponsor
Texas Plastic Surgery
Industry
Eligibility
25 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 25, 2026, 4:57 PM EDT
Terminated Phase 1 Interventional

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

NCT03840343
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
Interventions
Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 25, 2026, 4:57 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Adipose Derived Stem Cell Therapy for Autism

NCT01502488
View directory record Official record
Conditions
Autism
Interventions
Fat Harvesting and Stem Cell Injection
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
3 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 25, 2026, 4:57 PM EDT
Not listed Not applicable Interventional

The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

NCT03014401
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Arthroscopic debridement with stem cell transplantation, Arthroscopic debridement only
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
35 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
3
States / cities
Santa Monica, California • Stanford, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 25, 2026, 4:57 PM EDT
Not listed Phase 1 Interventional

Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis

NCT04043819
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
PSC-01
Drug
Lead sponsor
Personalized Stem Cells, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Carlsbad, California • La Mesa, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 25, 2026, 4:57 PM EDT
Not listed Not applicable Interventional

Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia

NCT02234778
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
TGI SVF material via intramuscular injection
Device
Lead sponsor
Tissue Genesis
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 25, 2026, 4:57 PM EDT
Not listed Phase 2 Interventional

Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury

NCT04136743
View directory record Official record
Conditions
Spinal Cord Injuries, Tendinopathy, Rotator Cuff Tears, Shoulder Pain
Interventions
Lipogems, Dexamethasone
Device · Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 25, 2026, 4:57 PM EDT